# Sight Sciences share price today (Sight Sciences, Inc., SGHT)

> Sight Sciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SGHT · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/sght

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $9.42 (+86.2% in a year)
- Revenue (Jun 2026): $23.4 M (+19.5% on a year ago)
- Profit (Jun 2026): −$4.4 M
- Operating margin: −16.6% (+43.0 points on a year ago)
- ROE: −60%, FY25
- ROIC: −12.0%, against a 17.1% cost of capital: −29.1 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Sight Sciences share price today? Sight Sciences, Inc.'s share price was $9.42 at the close on 3 November 2026. That is 56.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $9, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 23 weeks in a row. Over the last 1 year the share price moved +176% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Sight Sciences pay? Sight Sciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Sight Sciences on? Sight Sciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Sight Sciences profitable? Sight Sciences, Inc. posted a net loss of $4.4 M in the Jun 2026 quarter. The full FY25 year was a loss of $38.4 M. That loss is 19.0% of the quarter's revenue. The same quarter a year earlier lost $11.9 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Sight Sciences make, and is it growing? Sight Sciences, Inc. reported $23.4 M of revenue in the Jun 2026 quarter, +19.5% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 12.1% a year on average. The last full year, FY25, came in at $77.4 M. The last four reported quarters add to $83.4 M. FY25 revenue was $77.4 M, −3.1% on the year before. Recent pace: the last four quarters grew +9.4% on average, against 12.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.3%, against +2.5% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Sight Sciences keep? Sight Sciences, Inc.'s operating margin was −16.6% in the Jun 2026 quarter, 43.0 percentage points higher than the same quarter a year ago. Across 5 years it has been between −117.7% and −44.3%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +43.0 percentage points on the year while gross margin changed +6.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Sight Sciences' profit turning into cash? Sight Sciences, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $29.7 M of cash, against −$38.4 M of profit. After $224 K of spending on assets, free cash was −$29.9 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Sight Sciences' cash go? Sight Sciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.4 M on assets over the last 3 years. Averaged over those years that is 0.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.4 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Sight Sciences' P/E ratio, and how does it compare with its own history? Sight Sciences, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Sight Sciences, Inc. at 6.7× its FY25 revenue of $77.4 M. The P/E comes back here once profit turns positive. ## Is the Sight Sciences business getting better or worse? Sight Sciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Sight Sciences earn on its capital? Sight Sciences, Inc. earned a ROE of −60% in FY25. Its return on capital used (ROIC) is 29.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −49.7% net margin and 0.67× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −49.7% net margin × 0.67× asset turnover × 1.80× leverage (assets divided by equity) ≈ −59.9% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −12.0% − 17.1% = −29.1 percentage points. The 17.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Sight Sciences have too much debt? Sight Sciences, Inc. has total debt of $42.0 M against shareholder equity of $52.9 M as of Jun 2026, so its debt is 0.79× its equity. Year by year, that ratio went from 0.15 in FY21 to 0.64 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Sight Sciences shareholding pattern? 3.5% of Sight Sciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Sight Sciences from balance-sheet trouble? For Sight Sciences, Inc., the Z-score is −1.19. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.19 is inside the danger zone, so the balance sheet is a real risk. ## How does Sight Sciences rank in its industry? There is no score against its industry: Sight Sciences, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Sight Sciences compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Sight Sciences in size? Sight Sciences is the 52nd largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Cytek Biosciences, Inc., Pacific Biosciences of California, Inc. and Tactile Systems Technology, Inc. Just below it: Delcath Systems, Inc., AVITA Medical, Inc. and Cerus Corporation. ### Medical Devices companies close in size

1. [Cytek Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/ctkb) $775 million
2. [Pacific Biosciences of California, Inc.](https://www.sectoralpha.in/us/stocks/pacb) $758 million
3. [Tactile Systems Technology, Inc.](https://www.sectoralpha.in/us/stocks/tcmd) $561 million
4. Sight Sciences, Inc. $519 million
5. [Delcath Systems, Inc.](https://www.sectoralpha.in/us/stocks/dcth) $500 million
6. [AVITA Medical, Inc.](https://www.sectoralpha.in/us/stocks/rcel) $474 million
7. [Cerus Corporation](https://www.sectoralpha.in/us/stocks/cers) $472 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Concrete Pumping Holdings, Inc.](https://www.sectoralpha.in/us/stocks/bbcp) $516 million · Engineering & Construction
2. [Arvinas, Inc.](https://www.sectoralpha.in/us/stocks/arvn) $514 million · Biotechnology
3. Sight Sciences, Inc. $513 million
4. [Ethan Allen Interiors Inc.](https://www.sectoralpha.in/us/stocks/etd) $513 million · Furnishings, Fixtures & Appliances
5. [The York Water Company](https://www.sectoralpha.in/us/stocks/yorw) $513 million · Utilities - Regulated Water

## What else do people ask about Sight Sciences? ### What were Sight Sciences's latest quarterly results? Sight Sciences, Inc. reported revenue of $23.4 M and a net loss of $4.4 M for the Jun 2026 quarter. Earnings per share were −$0.08. The operating margin was −16.6%, 43.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Sight Sciences's market cap? Sight Sciences, Inc.'s market capitalisation is $519 M at a stock price of $9.42. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sight Sciences performing? Sight Sciences, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 23 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Sight Sciences's stock price go up? This page does not forecast Sight Sciences, Inc.'s stock price. What it shows instead: the stock price is $9.42. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Sight Sciences in its business cycle? Sight Sciences, Inc.'s FY25 operating margin was −44.3%, against a 5-year range of −117.7% to −44.3%: the middle of its own range, neither a peak nor a low. The latest quarter was −16.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sight Sciences story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sight Sciences a stock worth studying right now? What the numbers show: Sight Sciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.